Company currently initiating additional trial sites and working with study investigators to enroll participants IMNN-001 is the first and only immunotherapy to show meaningful overall survival benefit ...

Ovarian cancer is often diagnosed at an advanced stage due to vague symptoms like bloating and pelvic pain, making early ...

World Ovarian Cancer Day, observed on May 8, raises awareness, promotes early diagnosis, and calls for global action to ...

Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator BNT327, a bispecific antibody targeting PD-L1 and VEGF-A1, and mRNA c ...

In March 2025, at the Society of Gynecologic Oncology (“SGO”) Annual Meeting, preliminary data were presented from an ongoing Phase 1/2 clinical trial (NCT05438329) evaluating BNT325/DB-1305 ...

BioNTech invites investors and the general public to join a conference call and webcast with investment analysts today, May 5, 2025, at 8:00 a.m. EDT (2:00 p.m. CEST) to report its financial results ...

will be among the specialists sharing the biggest oncology research data of the year at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3 in Chicago ...

For people with low-risk, early-stage cervical cancer, a simple hysterectomy removing the uterus and cervix has similar ...

A vomiting-free ward protocol significantly reduced the effects of nausea and vomiting on QOL, anxiety, and depression, in patients with gynecologic cancers receiving chemotherapy.